Bung Hatta statue ,Bukittinggi

IKATAN DOKTER INDONESIA (IDI).Sumatera Barat

IKATAN DOKTER INDONESIA (IDI).Sumatera Barat
INDONESIAN MEDICAL ASSOCIATION

ASSALAMUALAIKUM........

dr Firman Abdullah SpOG / OBGYN

dr Firman Abdullah SpOG / OBGYN

Peer - Review..Cyberounds

FEEDJIT Live Traffic Feed

Discussion Board


ShoutMix chat widget

USG 3D/4D images (dr Firman Abdullah SpOG/ObGyn picture's )

free counters

FEEDJIT Live Traffic Map

FEEDJIT Recommended Reading

FEEDJIT Live Page Popularity

dr Firman Abdullah SpOG / OBGYN

dr Firman Abdullah SpOG / OBGYN

Saturday, November 6, 2010

Association between Bell's palsy in pregnancy and pre‐eclampsia

Developing Countries: free and reduced rate access

Association between Bell's palsy in pregnancy and pre‐eclampsia

  1. D. Shmorgun,
  2. W.‐S. Chan and
  3. J.G. Ray

+ Author Affiliations

  1. From the Department of Medicine, Sunnybrook and Women's College Health Science Centre, Toronto, Ontario, Canada
  • Received March 6, 2002.
  • Revision received March 12, 2002.

Abstract

Background: Previous published case series have suggested an association between the onset of Bell's palsy in pregnancy and the risk of pre‐eclampsia and gestational hypertension.

Aim: To evaluate the period of onset of Bell's palsy in pregnancy and the associated risk of adverse maternal and perinatal events, including the hypertensive disorders of pregnancy.

Study design: Case series study of consecutive female patients.

Methods: Women presenting with Bell's palsy during pregnancy or the puerperium were identified by a hospital record review at five Canadian centres over 11 years. Information was abstracted about each woman's medical and obstetrical history, period of onset of Bell's palsy, and associated maternal complications, including pre‐eclampsia and gestational hypertension as well as preterm delivery and low infant birth weight (<2500>

Results: Forty‐one patients were identified. Mean onset of Bell's palsy was 35.4 weeks gestation (SD 3.9). Nine (22.0%, 95%CI 10.8–35.7) were also diagnosed with pre‐eclampsia and three (7.3%, 95%CI 1.4–17.1) with gestational hypertension, together (29.3%, 95%CI 16.5–43.9) representing nearly a five‐fold increase over the expected provincial/national average. There were three twin births. The observed rates of Caesarean (43.6%) and preterm (25.6%) delivery, as well as low infant birth weight (22.7%), were also higher than expected, although the rate of congenital anomalies (4.5%) was not.

Conclusions: The onset of Bell's palsy during pregnancy or the puerperium is probably associated with the development of the hypertensive disorders of pregnancy. Pregnant women who develop Bell's palsy should be closely monitored for hypertension or pre‐eclampsia, and managed accordingly.

Introduction

In 1830, Sir Charles Bell described the association between idiopathic facial palsy (Bell's palsy) and pregnancy.1 The prevalence rate of Bell's palsy in pregnancy is estimated at 45.1 cases per 100 000 women, considerably higher than in the non‐pregnant population.2 In a systematic review, we observed that almost all cases of Bell's palsy were confined to the third trimester of pregnancy and the immediate postpartum period.3 Furthermore, there was a significantly higher rate of gestational hypertension and pre‐eclampsia (22.2%, 95%CI 12.5–36.4) among these cases, more than four times that found in the general obstetrical population.4

A limitation to previously published research into Bell's palsy in pregnancy is the absence of any systematic evaluation of important obstetrical and perinatal outcomes.3 Accordingly, these studies may have been biased toward underreporting of such events. We undertook this multi‐centre retrospective case series study with three principal objectives. First, to evaluate the timing of onset of Bell's palsy in pregnancy; second, to investigate the association between Bell's palsy and the hypertensive disorders of pregnancy; and third, to determine the prevalence of peripartum and perinatal outcomes among women who developed Bell's palsy during or immediately after pregnancy.

Methods

We reviewed the hospital charts of women diagnosed with Bell's palsy in pregnancy between 1990 and July 2001. Participants were identified through the Medical Records Departments of five Ontario hospitals: the Hamilton Health Sciences Corporation and St Joseph's Hospital, both in Hamilton; and the Sunnybrook and Women's College Health Sciences Centre, University Health Network, and Mount Sinai Hospitals, all in Toronto. A search for these charts was made using the ICD‐9CM diagnostic codes related to Bell's palsy and any concurrent pregnancy within ±12 months of the diagnosis of Bell's palsy.

From each hospital chart, we abstracted information on maternal demographics, past medical history, maternal complications during the index pregnancy, and mode of delivery. Gestational hypertension was defined as a blood pressure >140/90 mmHg after 20 weeks gestation, and pre‐eclampsia was defined as a blood pressure >140/90 mmHg, with the additional presence of at least 2+ proteinuria on dipstick or >300 mg of proteinuria over a 24‐h period. Abstracted perinatal outcomes included neonatal gestational age at birth, birth weight and the presence of any fetal anomalies detected in utero or at birth. We attempted to corroborate the chart data by contacting each patient by telephone. Perinatal outcomes and delivery information for these women were compared to rates previously described for the province of Ontario or Canada.

Using the current study data, we updated our previous systematic review3 to better estimate the rate of gestational hypertension and pre‐eclampsia among women with Bell's palsy during pregnancy or the puerperium. The rates from all studies were pooled using a random effects model,5 and the presence of significant heterogeneity for the pooled estimate was defined at a p value <0.10 id="xref-ref-6-1" class="xref-bibr" href="http://qjmed.oxfordjournals.org/content/95/6/359.full#ref-6">6

All abstracted data were entered into Microsoft Excel version 5.0c. Calculation of the pooled estimate of pre‐eclampsia and gestational hypertension was done using Meta‐Analyst 0.988.7 Permission to conduct this study was obtained from the Ethics Review Board of each participating medical centre. Permission to contact the women was obtained from their family physicians or obstetricians, and once contacted, each woman provided informed consent before being administered the telephone questionnaire.

Results

From the five hospitals, 41 women were diagnosed with unilateral Bell's palsy between 1990 and July 2001. The hospital charts were successfully reviewed for all 41 cases, and 19 women (46%) also had their information corroborated by telephone interview. For the remaining 22 women, either their telephone number was no longer in service, or written consent to contact them could not be obtained from their family physician or obstetrician.

The pre‐pregnancy characteristics of all 41 participants are listed in Table 1. The mean maternal age was 29.0 years (SD 6.0); the majority were nulliparous (36.6%) and there were three twin pregnancies. Few had a previous history of either chronic (one woman, 2.7%) or gestational hypertension (two women, 5.4%), and none (0%) had been diagnosed with pre‐eclampsia. One had experienced Bell's palsy previously, with a full recovery before the index pregnancy (Table 1).

The mean gestational age at the onset of Bell's palsy in the index pregnancy was 35.4 weeks gestation (SD 3.9). Only one woman (2.4%) presented before 27 weeks gestation, 33 (80.5%) between 27 and 42 weeks, four (9.8%) within the first week postpartum, while for three women (7.3%) the period of onset was not defined.

Nine women (22.0%, 95%CI 10.8–35.7) were diagnosed with pre‐eclampsia and three (7.3%, 95%CI 1.4–17.1) with isolated gestational hypertension. Thus, out of 41 women with Bell's palsy, 12 (29.3%, 95%CI 16.5–43.9) developed a hypertensive disorder, nearly five times the expected rate for Ontario/Canada (Table 2).

The overall mean neonatal birth weight was 3003.3 g (SD 873.8). The corresponding rates of Caesarean delivery (43.6%), preterm birth (25.6%) and low neonatal birth weight (22.7%) were comparably higher than expected (Table 2). Of the two neonates (4.5%) born with a detectable congenital anomaly, one had Down's syndrome and the other lethal fetal hydrops.

Using the current study data, in conjunction with those 11 studies included in our previous systematic review,3 the pooled rate of combined gestational hypertension or pre‐eclampsia was 25.0% (95%CI 8.3–55.2) among 203 women with Bell's palsy in pregnancy or the puerperium.

Table 1 

Pre‐pregnancy characteristics of women with onset of Bell's palsy during the index pregnancy or puerperium

Table 2 

Maternal and perinatal outcomes among women with onset of Bell's palsy during the index pregnancy or puerperium, compared to those previously described within the general population

Discussion

Of these 41 consecutive women, the majority presented with Bell's palsy during late pregnancy and the puerperium. They had an increased rate of the hypertensive disorders of pregnancy and operative delivery, while their infants experienced higher rates of preterm birth and low birth weight, compared to figures for the general population.

Study strengths and limitations

This study was probably biased by the retrospective collection of data, which was principally from the hospital charts of five large urban obstetrical centres. Since few clinicians were probably aware of the possible association between Bell's palsy and hypertension in pregnancy, it is unlikely that our estimates would have been much inflated by the presence of diagnostic suspicion bias, especially since we used objective definitions for the diagnosis of gestational hypertension and pre‐eclampsia. Although we included consecutive patients, and attempted to corroborate their chart data through telephone interviews, many could not be contacted, so some adverse perinatal events may have been missed or incorrectly recorded. In the absence of a concurrent control group, we had to rely upon national and provincial data to estimate the expected rates of adverse maternal and perinatal outcomes within the five participating centres. Such comparisons cannot account for possible differences between the women studied herein and those previously selected for large epidemiological studies. Finally, the presence of statistical heterogeneity for the pool estimate of pre‐eclampsia and gestational hypertension could be explained by the fact that previous investigators did not systematically assess for these events, or define them using standard criteria.3

Evidence for an association between Bell's palsy and pre‐eclampsia

Our results suggest that the vast majority of women who develop Bell's palsy in pregnancy had no known risk factors before pregnancy, including diabetes mellitus or chronic hypertension. As with previously published data, our findings support the hypothesis of an association between Bell's palsy and pre‐eclampsia.3 First, the observed rate of pre‐eclampsia was approximately five times higher than expected. Second, both disorders appeared late in pregnancy, and very rarely before the second trimester. Third, more women with Bell's palsy developed pre‐eclampsia (22%) than gestational hypertension (7.3%), suggesting that Bell's palsy and pre‐eclampsia may share a common pathway in their manifestation and pathogenesis, as outlined below.

Women in their third trimester of pregnancy may be predisposed to Bell's palsy due to the increase in maternal extracellular fluid volume during this period.12 Other nerve compression syndromes, including carpal tunnel syndrome,13 are also seen more commonly in the latter part of pregnancy.14 An increase in perineural oedema, resulting in facial nerve impingement, may form the underlying basis for facial nerve palsy.15 Pre‐eclampsia often manifests with considerable oedema within both subcutaneous and nervous system tissues,16 probably creating a neuro‐compressive effect. A second possible explanation may be the presence of a hypercoagulable state associated with pre‐eclampsia, resulting in thrombosis of the vasa nervorum, thereby leading to nerve ischemia and paralysis.15 Since the aetiology of Bell's palsy remains unknown, but is probably multifactorial,17 these and other mechanisms may provide insight into the treatment and recovery of ‘idiopathic’ facial palsy in pregnancy.

Clinical and research recommendations

Regardless of its aetiology, the notion that Bell's palsy in pregnancy may be associated with impending pre‐eclampsia cannot be overlooked. For these women, we recommend heightening maternal and fetal surveillance for the remainder of pregnancy. Although our data do not permit us to comment on the recovery of Bell's palsy after delivery, others have observed nearly 100% recovery in women with incomplete palsy, but only a 52% satisfactory outcome in the presence of a complete facial paralysis.18 Thus, research is needed to better characterize the association between Bell's palsy and pre‐eclampsia, and the relative rate of recovery of facial palsy in such cases. Investigators might also consider whether certain drugs used in the treatment of pre‐eclampsia (e.g. magnesium sulphate) can worsen the recovery of Bell's palsy,19 as well as the benefit of other therapies, including corticosteroids.20

Footnotes

References

Thursday, November 4, 2010

MMR vaccination and autism

News & RSS | Hitting the Headlines Archive | Article

HITTING THE HEADLINES

06 Feb 2008

MMR vaccination and autism


There is no link between the MMR vaccination and autism, reported eight newspapers (5 February 2008). The newspaper reports were based on a well-conducted case-control study and were generally accurate. The study findings are likely to be reliable.

  • On 5 February 2008, eight newspapers (1-8) reported that there is no link between the MMR vaccine and autism.

  • The reports were based on a study published in the Archives of Disease in Childhood (9). The study compared 98 vaccinated children aged 10-12 years with autism spectrum disorders (ASD) to two control groups (also vaccinated) comprising 52 children with special educational needs but no ASD and 90 typically developing children within the same geographical area. There was no evidence of a differential response to measles virus or the measles component of the MMR between children with ASD, with or without regression, and controls who had either one or two doses of MMR.

  • Six of the papers accurately report the key findings from the study and in two there is no reporting of the study results (7-8). The study appears well conducted and the conclusions are likely to be reliable. The findings of the study are in line with previous epidemiological studies showing no association between MMR vaccination and the development of autism.

Evaluation of the evidence base for measles vaccination and antibody response in autism spectrum disorders

Where does the evidence come from?

The research was conducted by Professor G Baird and colleagues from Guy's & St Thomas' NHS Foundation Trust in London and various hospitals and research institutes in the UK. The study was funded by the Department of Health, the Wellcome Trust, the National Alliance for Autism Research (NAAR) and Remedi.

What were the authors' objectives?

To test the hypothesis that measles vaccination was involved in the pathogenesis of autism spectrum disorders (ASD) as evidenced by signs of a persistent measles infection or abnormally persistent immune response in children with ASD who had been vaccinated against MMR compared with controls.

What was the nature of the evidence?

A community based case-control study was conducted of 240 children aged 10-12 years. Children with a diagnosis of ASD were identified among a cohort of 56,946 children from 12 districts in the South Thames Region of the UK. Controls with a statement of special educational needs (SEN) but no ASD diagnosis were identified from the same cohort. A second control group comprised typically developing children born at the same time and in the same area as the ASD cases. Children whose blood samples showed that they had received at least one MMR vaccination were eligible for the study.

How did participants differ on their level of exposure to the factor of interest?

A total of 235 children had received the first MMR vaccination: 98 with ASD, 52 SEN controls, and 85 typically developing controls. Stage 2 MMR vaccination was received by 106 children: 35 children with ASD, 18 SEN controls and 53 typically developing controls. Five children with no evidence of at least one MMR vaccination were excluded from the analysis. The particular factors of interest were the detection of the measles genome or measles antibody concentrations and whether these differed between the ASD group and the control groups. An additional factor of interest was whether the presence of bowel symptoms (enterocolitis) differed between the groups.

What were the findings?

No difference was detected in the distribution of measles antibody or in measles virus in ASD cases and controls whether the children had received the first, second or both MMR vaccinations. When the analysis was restricted to ASD cases with a history of regression there remained no difference between the groups. Only one child, who did not have ASD or regression, had symptoms of possible enterocolitis.

What were the authors' conclusions?

There is no association between measles vaccination and ASD. In this cohort children were less likely to receive the second MMR vaccination after diagnosis of a developmental problem.

How reliable are the conclusions?

The research was a well-conducted case-control study, the largest of its type to be undertaken, and the conclusions are likely to be reliable. ASD cases and SEN controls were located by screening a large cohort of children likely to be representative of the general population. The selection of the patients, and allocation into study groups, was based on the use of standardised tools for the diagnostic assessment of autism. Rigorous methods were used to assess both exposure to MMR vaccine and the presence of measles virus or antibodies to the virus. The typically developing control group was not obtained from a randomised selection process and through inviting participation in the study it is possible that a biased group elected to participate. The findings of the study are in line with previous epidemiological studies showing no association between MMR vaccination and the development of ASD.

Systematic reviews

Information staff at CRD searched for systematic reviews relevant to this topic. Systematic reviews are valuable sources of evidence as they locate, appraise and synthesize all available evidence on a particular topic.

There was one related systematic review identified on the Cochrane Database of Systematic Reviews (CDSR) (10) and two on the Database of Abstracts of Reviews of Effects (DARE) (11,12).

References and resources

1. The research that 'disproves MMR jab link to autism'. The Daily Mail, 5 February 2008, p4.

2. MMR and autism link is dismissed. The Times, 5 February 2008, p18.

3. MMR vaccine does not cause autism, says study. The Daily Telegraph, 5 February 2008, p7.

4. MMR links to autism dismissed by huge study. The Guardian, 5 February 2008, p1.

5. No link between the MMR jab and autism. Daily Mirror, 5 February 2008, p26.

6. Parents' anger over new 'evidence' that the MMR jab is safe. Daily Express, 5 February 2008, p17.

7. MMR jab given OK. The Sun, 5 February 2008, p21.

8. Autism 'is not linked to MMR'. The Independent, 5 February 2008, p13.

9. Baird G, Pickles A, Simonoff E [et al.]. Measles vaccination and antibody response in autism spectrum disorders. Archives of Disease in Childhood. Online publication February 5 2008 doi:10.1136/adc.2007.122937.

10. Demicheli V, Jefferson T, Rivetti A, Price D. Vaccines for measles, mumps and rubella in children. The Cochrane Database of Systematic Reviews 2005, Issue 4. Art. No.: CD004407. DOI: 10.1002/14651858.CD004407.pub2.

11. Jefferson T, Price D, Demicheli V, Bianco E, European Research Program for Improved Vaccine Safety. Unintended events following immunization with MMR: a systematic review. Vaccine 2003;21(25-26):3954-3960. [DARE Abstract]

12. Wilson K, Mills E, Ross C, McGowan J, Jadad A. Association of autistic spectrum disorder and the measles, mumps, and rubella vaccine: a systematic review of current epidemiological evidence. Archives of Pediatrics and Adolescent Medicine 2003;157(7):628-34. [DARE Abstract]

Consumer information

NHS - MMR the facts

Health Education Board for Scotland (HEBS) - MMR Information Centre

National Autistic Society

Previous Hitting the Headlines summaries on this topic

MMR not linked to autism: new study. Hitting the Headlines archive, 7 July 2006.

'Lingering fears of MMR-autism link dispelled'. Hitting the Headlines archive, 3 March 2005.

'Doctor's doubt on all-clear for MMR and autism link'. Hitting the Headlines archive, 11 October 2004.

MMR study finds no link with autism. Hitting the Headlines archive, 10 September 2004.

Bowel virus, autism and MMR. Hitting the Headlines archive, 13 January 2004.

'New research supports concern over MMR jab'. Hitting the Headlines archive, 16 December 2003.

Can mercury in jabs double the risk of autism? Hitting the Headlines archive, 19 November 2003.

The MMR vaccine and autism. Hitting the Headlines archive, 21 May 2003.

New study on MMR and autism. Hitting the Headlines archive, 7 November 2002.

'MMR may be linked to autism'. Hitting the Headlines archive, 9 August 2002.

Study finds no evidence of MMR and autism link. Hitting the Headlines archive, 12 &13 June 2002

What is the evidence for and against the MMR vaccine? Part 1. Hitting the Headlines archive, 7 February 2002.

What is the evidence for and against the MMR vaccine? Part 2. Hitting the Headlines archive, 7 February 2002.

Misreporting Measles Research. Hitting the Headlines archive, 6 February 2002.

The MMR vaccine debate. Hitting the Headlines archive, 24 September 2001.

Biggest study clears MMR jab. Hitting the Headlines archive, 12 January 2001.

Further information about Hitting the Headlines

Further information about Hitting the Headlines, together with selected relevant links, can be found at http://www.library.nhs.uk/hth/.





Publisher:
Centre for Reviews and Dissemination

Publication Date:
06 Feb 2008


BMI CALCULATOR

ACHMAD MOCHTAR GENERAL HOSPITAL BUKITTINGGI

ACHMAD MOCHTAR GENERAL HOSPITAL BUKITTINGGI
RUMAH SAKIT ACHMAD MOCHTAR BUKITTINGGI

Firman Abdullah Bung

drFirman Abdullah SpOG / ObGyn

drFirman Abdullah SpOG / ObGyn

KELUARGA BESAR TNI-AD

Dr Firman Abdullah SpOG/ OBGYN, Bukittinggi, Sumatera Barat ,Indonesia

Dr Firman Abdullah SpOG/ OBGYN,                              Bukittinggi, Sumatera Barat ,Indonesia

Bukittinggi , Sumatera Barat , Indonesia

Bukittinggi , Sumatera Barat  , Indonesia
Balaikota Bukittinggi

dr Firman Abdullah SpOG / OBGYN

dr Firman Abdullah SpOG / OBGYN

Ngarai Sianok ,Bukittinggi, Sumatera Barat.Indonesia

Ngarai Sianok ,Bukittinggi, Sumatera Barat.Indonesia

Brevet in Specialist Obstetric's & Gynecologist 1998

Brevet in Specialist Obstetric's & Gynecologist 1998
dr Firman Abdullah SpOG/ObGyn


Dokter Spesialis Kebidanan dan Penyakit Kandungan . ( Obstetric's and Gynaecologist ) . Jl.Bahder Johan no.227,Depan pasar pagi ,Tembok .Bukittinggi 26124 ,HP:0812 660 1614. West Sumatra,Indonesia

Sikuai Beach ,West Sumatra ,Indonesia

Sikuai Beach ,West Sumatra ,Indonesia

Fort de Kock, Bukittinggi